Omega-3 Ingredients Fair Trade Complaint? Not FDA's Bailiwick, Amarin Says
This article was originally published in The Rose Sheet
Executive Summary
The drug maker says it's not asking ITC to interpret the FD&C Act, but to investigate whether some omega-3 ingredient suppliers and marketers are failing to fulfill "certain marketplace expectations about the nature" of their products. ITC on Oct. 27 will vote on whether to investigate the complaint targeting a large part of the omega-3 market.